首页 | 本学科首页   官方微博 | 高级检索  
检索        

PD-L1过表达在DENV-2诱导血管内皮细胞自噬和凋亡中的作用机制
引用本文:姚峰,朱磊,程波,杨明,刘敏△.PD-L1过表达在DENV-2诱导血管内皮细胞自噬和凋亡中的作用机制[J].天津医药,2021,49(3):231-236.
作者姓名:姚峰  朱磊  程波  杨明  刘敏△
作者单位:江汉大学附属医院,武汉市第六医院综合三科(邮编430015)
基金项目:武汉市卫生与计划生育委员会科研项目(WX18C22,WX18D24,WX18D44)
摘    要:目的 探讨PD-L1过表达在Ⅱ型登革病毒(DENV-2)影响血管内皮细胞自噬和凋亡中的作用及机制。方法 以血管内皮细胞EAhy926为研究对象,以含梯度DENV-2(1×108~2×109 pfu/L)的无血清培养基处理细胞24 h和48 h,同时以无血清培养基处理细胞作为对照组,无血清培养基加入空白孔作为调零孔,MTT法检测细胞增殖活力。以PD-L1过表达慢病毒液和空载慢病毒液处理细胞,分别设空载对照组和转染组。DENV-2(1.2×109 pfu/L)处理细胞12、24、48 h作为DENV-2 12 h组、DENV-2 24 h组及DENV-2 48 h组,同时设置对照组(无血清培养基处理);另以DENV-2处理空载对照组和转染组48 h,以蛋白印迹法检测LC3B、Beclin-1及Bcl-2蛋白表达变化,流式细胞术检测各组细胞凋亡率。结果 1×108~2×109 pfu/L DENV-2可剂量依赖性抑制EAhy926细胞增殖,DENV-2 24 h和48 h的半数抑制浓度(IC50)分别是1.8×109 pfu/L和1.2×109 pfu/L。与对照组比较,DENV-2 12 h组、DENV-2 24 h组及DENV-2 48 h组LC3Ⅱ/LC3Ⅰ和Beclin-1蛋白表达上调,Bcl-2蛋白表达下调,细胞总凋亡率增加(均P<0.05)。与空载对照组比较,转染组PD-L1蛋白表达上调(P<0.01)。DENV-2处理48 h,与空载对照组相比,转染组LC3Ⅱ/LC3Ⅰ和Beclin-1蛋白表达下调,Bcl-2蛋白表达上调,细胞总凋亡率降低(均P<0.01)。结论 DENV-2通过上调LC3Ⅱ/LC3Ⅰ、Beclin-1蛋白表达及下调Bcl-2蛋白表达,从而诱导EAhy926细胞自噬和凋亡,而过表达PD-L1可抵抗DENV-2的诱导效应。

关 键 词:登革热病毒  内皮细胞  自噬  细胞凋亡  程序性细胞死亡受体-1配体  
收稿时间:2020-06-18
修稿时间:2020-12-16

The mechanism of PD-L1 overexpression in DENV-2 induced vascular endothelial cell autophagy and apoptosis
YAOFeng,ZHULei,CHENGBo,YANGMing,LIUMin△.The mechanism of PD-L1 overexpression in DENV-2 induced vascular endothelial cell autophagy and apoptosis[J].Tianjin Medical Journal,2021,49(3):231-236.
Authors:YAOFeng  ZHULei  CHENGBo  YANGMing  LIUMin△
Institution:Department of INTEGRATED 3, the Affiliated Hospital of Jianghan University, the Sixth Hospital of Wuhan, Wuhan 430015, China
Abstract:Objective To investigate the role and mechanism of PD-L1 overexpression in the effect of dengue virus type Ⅱ (DENV-2) on vascular endothelial cell autophagy and apoptosis. Methods The vascular endothelial cell EAhy926 was used as the research object. The cells were treated with serum-free medium containing DENV-2 (1×108-2×109 pfu/L) for 24 h and 48 h. At the same time, cells were treated with serum-free medium as control group. Add serum-free medium to blank holes as zero adjustment holes. The cell proliferation activity was detected by MTT method. The cells were treated with PD-L1 overexpression lentiviral solution and no-load lentiviral solution, and cells were set as no-load control group and transfection group respectively. Cells treated with DENV-2 (1.2×109 pfu/L) for 12 h, 24 h and 48 h were set as DENV-2 12-h group, DENV-2 24-h group and DENV-2 48-h group, respectively. At the same time, the control group was set (cells treated with serum-free medium). In addition, the no-load control group and the transfection group were treated with DENV-2 for 48 hours, and the protein expression changes of LC3B, Beclin-1 and Bcl-2 were detected by Western blot assay. The cell apoptosis was detected by flow cytometry. Results 1×108-2×109 pfu/L DENV-2 can inhibit the proliferation of EAhy926 cells in a dose-dependent manner, with IC50 of 1.8×109 pfu/L and 1.2×109 pfu/L, respectively. Compared with the control group, the expression leves of LC3Ⅱ/LC3Ⅰ and Beclin-1 protein were up-regulated in the DENV-2 12-h group DENV-2 24-h group and DENV-2 48 h group, the expression of Bcl-2 protein was down-regulated, and the total cell apoptosis rate was increased (P<0.05). Compared with the empty control group, the expression of PD-L1 protein was up-regulated in the transfection group (P<0.01). After DENV-2 treatment for 48 hours, compared with the no-load control group, the expressions of LC3Ⅱ/LC3Ⅰ and Beclin-1 protein were down-regulated in the transfection group, the expression of Bcl-2 protein was up-regulated, and the total cell apoptosis rate was reduced (P<0.01). Conclusion DENV-2 induces autophagy and apoptosis in EAhy926 cells by up-regulating LC3Ⅱ/LC3Ⅰ, Beclin-1 protein expression and down-regulating Bcl-2 protein expression, while the overexpression of PD-L1 can resist the inducing effect of DENV-2.
Keywords:dengue virus  endothelial cells  autophagy  apoptosis  programmed cell death receptor-1 ligand  
点击此处可从《天津医药》浏览原始摘要信息
点击此处可从《天津医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号